Next, we investigated if the sensitizing action of TSPAN1 depletion could be extended to other therapeutic drugs, such as dasatinib, a dual SRC/ABL kinase inhibitor actively tested in various clinical trials, including HNSCC [29,30] (www.clinicaltrials.gov). The gene discussed is TSPAN1; the disease is head and neck squamous cell carcinoma.